Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug
暂无分享,去创建一个
Ralph Weissleder | Suresh Gadde | Omid C Farokhzad | Yoshiko Iwamoto | Miles A. Miller | Stephen J Lippard | R. Weissleder | Y. Iwamoto | O. Farokhzad | S. Lippard | M. Pittet | Rainer H. Kohler | C. Engblom | Katherine S Yang | S. Gadde | B. Askevold | Camilla Engblom | Christina Pfirschke | Nagesh Kolishetti | Rainer H Kohler | Harshal R. Zope | Miles A Miller | Harshal Zope | Yao-Rong Zheng | C. Pfirschke | N. Kolishetti | Mikael Pittet | Bjorn Askevold | Yao-Rong Zheng | Katherine S. Yang | Nagesh Kolishetti | Camilla Engblom
[1] L. Johansson,et al. Fluorescence and Absorption Spectroscopic Properties of Dipyrrometheneboron Difluoride (BODIPY) Derivatives in Liquids, Lipid Membranes, and Proteins , 1994 .
[2] M. Bally,et al. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. , 1997, The Journal of pharmacology and experimental therapeutics.
[3] R. Vile,et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Y. Sugiyama,et al. Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[5] R. Weissleder,et al. Imaging inflammation of the pancreatic islets in type 1 diabetes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[6] G. Wahl,et al. Cellular Dynamics Visualized in Live Cells in Vitro and in Vivo by Differential Dual-Color Nuclear-Cytoplasmic Fluorescent-Protein Expression , 2004, Cancer Research.
[7] Colleen A Crane,et al. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] K. Avgoustakis,et al. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. , 2005, International journal of pharmaceutics.
[9] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[10] R. Schwendener,et al. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach , 2006, British Journal of Cancer.
[11] Meng Yang,et al. Whole-body subcellular multicolor imaging of tumor-host interaction and drug response in real time. , 2007, Cancer research.
[12] G. Soma,et al. Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[13] R. Weissleder,et al. Utility of a new bolus-injectable nanoparticle for clinical cancer staging. , 2007, Neoplasia.
[14] L. Luo,et al. A global double‐fluorescent Cre reporter mouse , 2007, Genesis.
[15] A. Koch. The pathogenesis of rheumatoid arthritis. , 2007, American journal of orthopedics.
[16] M. Amiji,et al. Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. , 2007, Journal of pharmaceutical sciences.
[17] L. Kèlland,et al. The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.
[18] Robert Langer,et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.
[19] G. Jung,et al. Comparative photostability studies of BODIPY and fluorescein dyes by using fluorescence correlation spectroscopy. , 2008, Chemphyschem : a European journal of chemical physics and physical chemistry.
[20] Anthony Harriman,et al. The chemistry of fluorescent bodipy dyes: versatility unsurpassed. , 2008, Angewandte Chemie.
[21] T. Jacks,et al. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.
[22] M. Czech,et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation , 2009, Nature.
[23] Sujay Chattopadhyay,et al. Polymer- and liposome-based nanoparticles in targeted drug delivery. , 2010, Frontiers in bioscience.
[24] Steven J. M. Jones,et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. , 2010, The New England journal of medicine.
[25] Robert Langer,et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy , 2010, Proceedings of the National Academy of Sciences.
[26] Zhao-You Tang,et al. Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects , 2010, Clinical Cancer Research.
[27] Cui Tang,et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. , 2010, Biomaterials.
[28] F. Ginhoux,et al. Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages , 2010, Science.
[29] K. Moore,et al. Macrophages in the Pathogenesis of Atherosclerosis , 2011, Cell.
[30] Drew A. Torigian,et al. CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.
[31] Kit S Lam,et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. , 2011, Biomaterials.
[32] Omid C Farokhzad,et al. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo , 2011, Proceedings of the National Academy of Sciences.
[33] Ralph Weissleder,et al. Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. , 2011, Cancer research.
[34] J. Brenton,et al. Evolution of platinum resistance in high-grade serous ovarian cancer. , 2011, The Lancet. Oncology.
[35] W. Zamboni,et al. Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier‐Mediated Anticancer Agents , 2012, Clinical pharmacology and therapeutics.
[36] Jae-Hyun Park,et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.
[37] Robert Langer,et al. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.
[38] Ran Kafri,et al. Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase. , 2012, Molecular cell.
[39] Yuquan Wei,et al. Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature , 2012, PloS one.
[40] Daniel G. Anderson,et al. Origins of tumor-associated macrophages and neutrophils , 2012, Proceedings of the National Academy of Sciences.
[41] R. Langer,et al. Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. , 2013, ACS nano.
[42] Robert Langer,et al. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug , 2013, Proceedings of the National Academy of Sciences.
[43] Christina S. Leslie,et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.
[44] H. Maeda,et al. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.
[45] M. Zucchetti,et al. Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.
[46] Greg M. Thurber,et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo , 2013, Nature Communications.
[47] Robert Langer,et al. Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. , 2012, Nanomedicine.
[48] C. Lewis,et al. Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.
[49] Z. Gu,et al. The potential of self-assembled, pH-responsive nanoparticles of mPEGylated peptide dendron-doxorubicin conjugates for cancer therapy. , 2013, Biomaterials.
[50] R. Jain,et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.
[51] H. Tsuchiya,et al. Imaging UVC‐induced DNA damage response in models of minimal cancer , 2013, Journal of cellular biochemistry.
[52] Jianghong Rao,et al. Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. , 2014, Small.
[53] Miles A. Miller,et al. Platinum Compounds for High‐Resolution In Vivo Cancer Imaging , 2014, ChemMedChem.
[54] Ralph Weissleder,et al. Imaging windows for long-term intravital imaging , 2014, Intravital.
[55] Ralph Weissleder,et al. Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor , 2014, Scientific Reports.
[56] M. Nahrendorf,et al. Cardiac macrophages and their role in ischaemic heart disease. , 2014, Cardiovascular research.
[57] Jessica Wright. Nanotechnology: Deliver on a promise , 2014, Nature.
[58] Jessica Wright. Deliver on a promise. , 2014, Scientific American.
[59] F. Hazard,et al. Cancer Therapy: Development of Novel Tumor‐Targeted Theranostic Nanoparticles Activated by Membrane‐Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy (Small 3/2014) , 2014 .
[60] Linda G. Griffith,et al. Molecular Network Analysis of Endometriosis Reveals a Role for c-Jun–Regulated Macrophage Activation , 2014, Science Translational Medicine.
[61] R. Weissleder,et al. Imaging macrophages with nanoparticles. , 2014, Nature materials.
[62] Xiaoyang Xu,et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.
[63] S. Lippard,et al. Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery , 2014, Journal of the American Chemical Society.
[64] Travis M. Shaffer,et al. Environment-responsive Nanophores for Therapy and Treatment Monitoring via Molecular MRI Quenching , 2014, Nature Communications.
[65] D. Linehan,et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.
[66] E. Winer,et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] Ashley M. Laughney,et al. Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin , 2014, Science Translational Medicine.
[68] J. Blay,et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.
[69] Gregory L. Szeto,et al. Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.
[70] S. Gadde. Multi-drug delivery nanocarriers for combination therapy , 2015 .
[71] A META-ANALYSIS OF THE LITERATURE , 2017 .